Solid Biosciences
SLDB | NASDAQ
$6.48
-$0.36 (-5.26%)
At close: Nov 16, 2026, 4:00 PM ET
$6.51
+$0.03 (+0.46%)
After-hours:
Nov 16, 2026, 7:50 PM ET
-5.26%
(1D)No price chart data available for 1D timeframe.
Rating
29.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #829/1021 (Top 81%)
Key Statistics
Market Data
Market Cap $978.69M
1D Range
6.46 6.94
52W Range
4.34 11.15
Valuation (TTM)
PE -3.62
PB 2.86
EV/EBITDA -2.98
Valuation (NTM)
Forward PE N/A
Forward PEG 0.18
Price Target $22.50
Cash Flow
FCF Yield -20.5%
SBC Adj. FCF Yield -22.9%
SBC Impact -11.7%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
-100.0%
Dil EPS 3Y | 5Y 20.9% |
48.3%
FCF 3Y | 5Y -38.3% |
-20.0%
Returns
ROA -55.2%
ROE -67.8%
ROIC -61.3%
Financial Health
Net Cash
$329.3M
Current Ratio 11.99
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene tran...
Sector Healthcare
Industry Biotechnology
Employees 121
IPO Date Jan 26, 2018
Website www.solidbio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
8
Consensus
Buy
Price Target
$22.50
Upside
+247.22%
Buy (8)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove SLDB